AstraZeneca and Merck have moved to pull Lynparza’s approval as a fourth-line treatment for BRCA-mutated advanced ovarian cancer. Confirmatory phase 3 trial data showed an increased risk of death among Lynparza patients that had already received at least three other rounds of chemotherapy. The move follows GSK’s Sept. 14 decision to withdraw its own PARP inhibitor, Zejula, in previously treated ovarian cancer with homologous recombination deficiency. For the treatment of ovarian cancer, Lynparza currently holds covered or better status for 99% of all insured lives. 15% of lives have unrestricted preferred access to Lynparza, growing to 50% with restrictions applied.
SOURCE: MMIT Analytics, as of 9/28/22